Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer
Chemotherapy is the main treatment for triple-negative breast cancer (TNBC), a subtype of breast cancer that is aggressive with a poor prognosis. While chemotherapeutics are potent, these agents lack specificity and are equally toxic to cancer and nonmalignant cells and tissues. Targeted therapies f...
Main Authors: | Azam Saghaeidehkordi, Shiuan Chen, Sun Yang, Kamaljit Kaur |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/5/661 |
Similar Items
-
A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy
by: Shurong Liu, et al.
Published: (2023-02-01) -
Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer
by: Levente E. Dókus, et al.
Published: (2020-06-01) -
Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
by: Shen-Jun Yuan, et al.
Published: (2019-10-01) -
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
by: Jakob Lindberg, et al.
Published: (2021-10-01) -
Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy
by: Aleksandra Hawryłkiewicz, et al.
Published: (2021-01-01)